GSA Capital Partners LLP Invests $481,000 in Edwards Lifesciences Co. (NYSE:EW)

GSA Capital Partners LLP bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 7,291 shares of the medical research company’s stock, valued at approximately $481,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Bank of New York Mellon Corp raised its stake in Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after purchasing an additional 809,605 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Edwards Lifesciences by 57.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after purchasing an additional 2,390,137 shares in the last quarter. AustralianSuper Pty Ltd raised its stake in Edwards Lifesciences by 17.8% in the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock worth $216,013,000 after purchasing an additional 494,604 shares in the last quarter. Ownership Capital B.V. raised its stake in Edwards Lifesciences by 1.2% in the 3rd quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company’s stock worth $197,509,000 after purchasing an additional 34,597 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in Edwards Lifesciences by 2.1% in the 2nd quarter. American Century Companies Inc. now owns 2,082,961 shares of the medical research company’s stock worth $192,403,000 after purchasing an additional 43,247 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Robert W. Baird decreased their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Canaccord Genuity Group decreased their target price on shares of Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a report on Friday, October 25th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and an average price target of $75.67.

Insider Buying and Selling

In other news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 40,000 shares of company stock worth $2,657,000 in the last ninety days. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Up 0.4 %

NYSE:EW opened at $70.20 on Wednesday. The firm’s 50 day simple moving average is $67.59 and its 200 day simple moving average is $75.91. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a market cap of $41.40 billion, a PE ratio of 10.13, a P/E/G ratio of 3.81 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the company earned $0.59 EPS. The firm’s revenue was up 8.9% compared to the same quarter last year. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.